Ticagrelor Tablet, Film Coated
Product Images NDC 71610-914

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 71610-914). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (71610 0914 41)

Label (71610 0914 41)
TICAGRELOR 90 mg film-coated tablets packaging label showing a quantity of 5400 tablets. The label includes storage instructions, manufacturer InvaGen Pharmaceuticals in Central Islip, NY, and repackager Aphena Pharma Solutions in Cookeville, TN. The NDC number 71610-914-41 is shown along with batch, GTIN, and expiration information.*
FDA Label Image

Aphena (Aphena)

Aphena (Aphena)
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A cumulative percentage line graph comparing the events over 360 days from the first dose for Ticagrelor 90 mg and Clopidogrel. The graph shows the cumulative percentage on the y-axis and days from first study dose on the x-axis. Data includes numbers at risk and event percentages for both drugs at 12 months.*
FDA Label Image

Figure 10 (Figure 10)

Figure 10 (Figure 10)
A Kaplan-Meier cumulative event curve comparing Ticagrelor 90 mg with Clopidogrel over 360 days from randomization. The graph shows cumulative percentage of events, with Ticagrelor represented by a solid line and Clopidogrel by a dashed line, including risk numbers at various time points. A data inset provides patient counts, event rates, hazard ratio with confidence interval, and p-value.*
FDA Label Image

Figure 11 (Figure 11)

Figure 11 (Figure 11)
A forest plot chart comparing the overall treatment effect of Ticagrelor versus Clopidogrel across various subgroups, including geographic region, ASA dose, planned treatment approach, patients undergoing CABG, diabetes history, prior TIA/stroke, glycoprotein IIb/IIIa inhibitor use, age group, sex, and race. It displays hazard ratios with 95% confidence intervals, showing data for event numbers, percentages, and annualized rates for both treatments.*
FDA Label Image

Figure 12 (Figure 12)

Figure 12 (Figure 12)
A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals (CI) for Ticagrelor versus Clopidogrel across different aspirin dose (ASA Dose) categories (>=300 mg, >100 to <300 mg, <=100 mg) in US and Non-US regions. The plot shows data points and confidence bars illustrating relative effectiveness, with a scale indicating whether Ticagrelor or Clopidogrel is favored.*
FDA Label Image

Figure 13 (Figure 13)

Figure 13 (Figure 13)
A line graph depicting cumulative event percentages over days from randomization for three groups: Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo. The x-axis represents days up to about 1320, and the y-axis shows cumulative percentage from 0 to 11%. Ticagrelor groups have lower cumulative percentages than placebo. A risk table below shows the number of patients at risk over time for each group.*
FDA Label Image

Figure 14 (Figure 14)

Figure 14 (Figure 14)
A forest plot chart comparing the overall treatment effect of Ticagrelor 90 mg with placebo across various patient subgroups. The chart shows hazard ratios with 95% confidence intervals, patient counts, and event rates per year. Subgroups analyzed include age, sex, race, weight, geographic region, history of myocardial infarction, diabetes status, renal function, and stent type, visually presenting comparative efficacy between Ticagrelor and placebo.*
FDA Label Image

Figure 15 (Figure 15)

Figure 15 (Figure 15)
A cumulative percentage line chart depicting data from a comparative study between Ticagrelor and placebo over 54 months from randomization. The chart shows two lines, one solid representing Ticagrelor and one dashed for placebo, with cumulative percentages on the y-axis and months on the x-axis for patient event outcomes.*
FDA Label Image

Figure 16 (Figure 16.jpg)

Figure 16 (Figure 16.jpg)
A forest plot comparing hazard ratios (HR) with 95% confidence intervals (CI) for ticagrelor versus placebo across various patient characteristics related to age, sex, race, body mass index, geographic region, aspirin dose, HbA1c, eGFR, insulin use, medical history, prior procedures, current smoking status, and duration of diabetes. The plot visually depicts subgroup analyses indicating whether ticagrelor or placebo is favored.*
FDA Label Image

Figure 17 (Figure 17)

Figure 17 (Figure 17)
A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg twice daily and placebo over 34 days from randomization. The solid line represents Ticagrelor with a cumulative percentage up to about 5.4%, while the dashed line represents placebo with a cumulative percentage up to about 6.5%. Numbers at risk for each group are shown below the x-axis, which represents days from randomization; the y-axis shows cumulative percentage.*
FDA Label Image

Figure 18 (Figure 18.jpg)

Figure 18 (Figure 18.jpg)
A forest plot chart displaying hazard ratio (HR) with 95% confidence intervals (CI) for various patient characteristics comparing Ticagrelor versus placebo. The chart includes subgroups by age, sex, race, weight, BMI, geographic region, diagnosis, stroke severity, time factors, comorbidities, prior treatments, and smoking status. Each subgroup shows sample sizes, HR values with confidence intervals, and visually represents effectiveness comparison between Ticagrelor and placebo.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A bar chart showing the percentage of patients who had an event following coronary artery bypass grafting (CABG) over a period of days. The chart compares two groups labeled T and C across days 1 through 7 and 8 or more. Numerical event counts over total patients are listed below each day for both groups.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A line chart depicting cumulative percentage over months from randomization comparing Ticagrelor and placebo groups. The X-axis represents months from 0 to 54, and the Y-axis shows cumulative percentage from 0 to 7%. Two lines represent Ticagrelor (solid) and placebo (dashed), with Ticagrelor showing higher cumulative percentages. The chart includes numbers at risk below the X-axis for both groups at various time points.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg twice daily versus placebo. The X-axis represents days from randomization, and the Y-axis shows cumulative percentage. The graph includes risk numbers over time for both groups and presents event counts and KM percentages for each treatment.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
Line graph showing IPA (%) induced by 20μM ADP over time (hours) comparing three treatments: Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo. Ticagrelor achieves the highest IPA rapidly and sustains it, Clopidogrel shows moderate increase progressively, and Placebo remains low throughout.*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
A line graph showing IPA (%) induced by 20 uM ADP over time comparing Ticagrelor, Clopidogrel, and Placebo. The x-axis represents time in days, and the y-axis shows IPA percentage. Data points for Ticagrelor (circles), Clopidogrel (triangles), and Placebo (squares) indicate varying inhibition levels over 10 days. An inset graph displays IPA percentage over 48 hours for the same treatments.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
A forest plot chart showing the mean effect and 90% confidence intervals for Ticagrelor and AR-C124910XX across intrinsic factors such as age, gender, ethnicity, renal impairment, end stage renal disease on hemodialysis, and hepatic impairment. It compares changes relative to reference in PK parameters Cmax and AUC with corresponding recommendations, mainly indicating no dose adjustment is needed.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
A chart titled 'Mean effect and 90% CI' showing the pharmacokinetic effects of various interacting drugs on Ticagrelor and AR-C124910XX. It plots changes relative to reference for Cmax and AUC values, categorizing drugs such as CYP3A4 inhibitors, inducers, aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl, with corresponding recommendations on dose adjustments or use.*
FDA Label Image

Figure 9 (Figure 9)

Figure 9 (Figure 9)
A chart displaying drug interactions with Ticagrelor doses, showing the mean effect and 90% confidence intervals for changes relative to the interacting drug alone. It includes different drugs such as Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine with corresponding dopamine doses and recommendations on dose adjustments.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Ticagrelor, depicting its molecular composition and arrangement, including multiple rings and functional groups such as hydroxyls and fluorinated aromatic rings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.